PTEN, VEGF, HER2 and P53 Status and Bevacizumab Response of Colorectal Cancer Patients

PTEN, VEGF, HER2 and P53 Status and Bevacizumab Response of Colorectal Cancer Patients

Asian Pacific J Cancer Prev, 13 (12), 6397-6401

RESEARCH ARTICLE

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

Oguz Kara¹, Berna Bozkurt Duman¹*, Banu Kara³, Seyda Erdogan³, Cem Kaan Parsak⁴, Gürhan Sakman⁴

Abstract

Background: No factor has thus far been identified to predict the efficacy of bevacizumab therapy for colorectal cancer. We here therefore studied PTEN, VEGF, HER2 and p53 by immunohistochemistry as possible prognostic and predictive factors. Materials and Methods: A total of 34 retrospectively collected tumor samples were evaluated, all from patients receiving bevacizumab-based regimens. VEGF-A, PTEN, HER2, p53 were assessed and data was compared with clinicopathologic characteristics of patients and the bevacizumab response rate. Results: In this study, the median age of the 34 metastatic colorectal cancer patients was 55.5 (24-75), twelve (35.3%) being women and 22 (64.7%) men. PTEN, VEGF, HER2, p53 expressions were compared with bevacizumab response and other characteristics of disease. Statistical significant differences were not found between bevacizumab response rates and different expression levels of VEGF, PTEN, HER2 and p53 (respectively p=0.256, p=0.832, p=0.189, p=0.131). However, a survival difference was noted in the VEGF expression negative group (median OS:55 months; 95%CI, 22-88 months) (p=0.01). There was no statistically significant OS difference in other groups (PTEN p=0.6, HER2 p=0.189, p53 p=0.13). Conclusions: We did not find any predictive factor for BV therapy in our study. VEGF negative expression could be an important prognostic factor in metastatic colorectal carcinoma.

Keywords: Bevacizumab - VEGF - PTEN - HER2-neu - p53 - colorectal cancer

Introduction

Colorectal carcinoma is the third common cause of cancer related mortality in the world (Jemal et al., 2008). Targeted biologic agents has increased the overall median survival in metastatic colorectal carcinoma to 23.5 months (Van Cutsem et al., 2011). Kirsten–ras (KRAS) mutation in the epidermal growth factor receptor (EGFR) pathway has changed the chemotherapy to a more personalized therapy, tailored approach with respect to the use EGFR monoclonal antibodies (Wong et al., 2008). Despite numerous studies, an equivalent predictive biomarker for bevacizumab has not been identified (Asghar et al., 2010). PTEN loss, VEGF, HER2 are responsible for tumor angiogenesis, cell proliferation, apoptosis regulation by different pathways (Asghar et al., 2010; Cacheux et al., 2011). The primary function of the p53 protein is as a tumour suppressor (Christos et al., 2004; Munro et al., 2005) (Figure 1).

In the guidance of this functions of these biomarkers we analysed PTEN, VEGF, HER2 and p53 expressions by immunohistochemistry for determining BV response in metastatic colorectal carcinoma.

Materials and Methods

Patients with a diagnosis of histologically proven colorectal carcinoma between 2000-2009 years were eligible for our study. Ninety patients were analysed
retrospectively and we collected 34 tumor samples from the patients with colorectal carcinoma that treated in Cukurova University Medical Faculty. The other patients were excluded due to incomplete data. All of the patients received bevacizumab in combination with FOLFIRI or FOLFOX. VEGF, PTEN, HER2, p53 status were determined by immunohistochemistry (IHC) before treatment. Tumor Node Metastasis staging system was used to staging the patients. Response was evaluated by RECIST criteria. VEGF, PTEN, HER2, p53 expression rates in colorectal carcinoma in Table 1.

VEGF staining quantity was scored as follows: no staining is 0, 1-10% of cells stained are scored as 1, 11-50% as 2, 51-80% as 3 and 81-100% as 4. Staining intensity was scored on a scale of 0-3 where 0 is no staining, 1 is weak, 2 is moderate and 3 is strong. The staining intensity score and staining quantity score were multiplied to give the immunohistochemical scor (IHS). An IHS of 9-12 was considered strong immunoreactivity; 5-8 moderate, 1-4 weak and 0 was considered as negative (Perrone et al., 2006). PTEN, p53. Staining of cells was scored as negative if <10%, +1 if 10-50% and +2 if >50% of slide’s area was stained positive (Sarmadi et al., 2009).

HER2-neu, a score of 0 was given to those specimens showing no staining, or membrane staining in <10% of the tumor cells. A score of 1+ was given to a specimen showing faint or barely perceptible membrane staining in >10% of tumor cells. A score of 2+ was given to specimens showing weak to moderate complete membrane staining in >10% of tumor cells. A score of 3+ was given to specimens showing strong complete membrane staining in >10% of tumor cells (Ahwon et al., 2007).

### Statistical analysis
Data was compared with clinicopathologic characteristics of patients. Khi2 test was used for categoric measurements between groups. Progression free survival was analyzed using Kaplan-Meier plots and log rank test. Data are reported as mean S.D ±, median (range) or proportions. Estimates of overall survival with associated 95%CIs were obtained using the Kaplan–Meier method. The calculations were performed using SPSS 16.0 for Windows (SPSS, Chicago, IL, USA).

### Results

Thirty-four CRCs analyzed in this study: 12 (64.7%) patients were woman and 22 (35.3%) patients were man. Median age was 55.5 (24-75). Five patients (14.7 %), were Stage II, 10 (29.4%) patients were Stage III, 19 (55.9 %) were Stage IV at the time of diagnosis. All patients were metastatic and treated with bevacizumab-based regimens at the time of inclusion to the study.

The correlation between expression levels of HER2, VEGF, PTEN, p53 were analysed. Statistically significant difference was not found between expressions.

Time to progression was 15±6.8 months in patients. Time to progression in VEGF negative expression group was 16.4±7.9 months and 14.3±6.2 months in VEGF expression positive group (p=0.53). Time to progression in PTEN negative expression group was 14±7.5 months and 15±6.4 months in PTEN expression positive group (p=0.392). Time to progression in HER2 negative expression group was 14.6±6.1 months and 17±4.5 months in HER2 expression positive group (p=0.53). Time to progression in p53 negative expression group was 16.2±8.5 months and 13.9±4.8 months in p53 expression positive group (p=0.392). Statistically significant difference was not found between time to progression and VEGF, PTEN, HER2, p53 expression.

VEGF, PTEN, HER2 and p53 expressions were divided into two groups in subgroup analysis. Negative expression was classified as negative and other all levels of expressions were classified as positive group (Figure 2).

In this subgroup analysis statistically significant difference was not found between VEGF, PTEN, HER2

![Figure 1. Important Cellular Mediators Cancer Growth. PTEN and HER-2/neu regulate the phosphatidylinositol 3-kinase (PI3-Kinase)/Akt signaling pathway, which, in turn, regulates the activity of important mediators of proliferation, survival, and apoptosis (Christos et al., 2004)](image)

![Figure 2. Expression and OS (Overall Survival). a) VEGF, b) PTEN, c) HER2-neu, d) p53 and e) VEGF](image)
Table 1. VEGF, PTEN, HER2, p53 Expression Rates in Colorectal Carcinoma

| Expression       | Responder No (%) | Non-responder No (%) | p    |
|------------------|------------------|----------------------|------|
| VEGF Negative    | 11 (32.4)        | 7 (35)               | 0.256|
| Weak             | 3 (21.4)         | 5 (32)               |      |
| Moderate         | 6 (23.1)         | 3 (25)               |      |
| Strong           | 1 (7.1)          | 2 (11)               |      |
| PTEN Negative    | 12 (35.3)        | 10 (29.4)            |      |
| 1+               | 2 (5.9)          |                      |      |
| 2+               | 2 (9)            |                      |      |
| HER2 Negative    | 28 (82.4)        | 4 (11.8)             |      |
| 1+               | 1 (7.1)          |                      |      |
| 2+               | 2 (5.9)          |                      |      |
| p53 Negative     | 16 (47.1)        | 4 (11.8)             |      |
| Strong           | 6 (17.6)         | 5 (25)               |      |
| Moderate         | 9 (26.5)         | 3 (15)               |      |

Table 2. Impact of VEGF, PTEN, HER2, p53 Expression to Response Rate of Bevacizumab Containing Regimens

| Bevacizumab containing regimen response status | Responder No (%) | Non-responder No (%) | p    |
|----------------------------------------------|------------------|----------------------|------|
| VEGF Negative                               | 4 (28.6)         | 7 (35)               | 0.256|
| Weak                                        | 3 (21.4)         | 5 (25)               |      |
| Moderate                                    | 6 (42.9)         | 3 (15)               |      |
| Strong                                      | 1 (71)           | 2 (11)               |      |
| PTEN Negative                               | 5 (35.7)         | 7 (35)               | 0.832|
| 1+                                           | 4 (28.6)         | 6 (30)               |      |
| 2+                                           | 5 (35.7)         | 7 (35)               |      |
| HER2 Negative                               | 11 (78.6)        | 17 (85)              | 0.189|
| 1+                                           | 3 (21.4)         | 1 (5)                |      |
| 2+                                           | 0 (0)            | 2 (10)               |      |
| P53 Negative                                | 4 (28.6)         | 12 (60)              | 0.131|
| 1+                                           | 3 (21.4)         | 1 (5)                |      |
| 2+                                           | 7 (50.0)         | 7 (35)               |      |

Table 3. Association between LVI, PNI, Differentiation and VEGF, PTEN, p53

| Leniovascular Invasion (p%) | Perineural Invasion (p%) | Differentiation (p%) |
|-----------------------------|-------------------------|----------------------|
| VEGF                        | 0.32                    | 0.255                | 0.48                |
| PTEN                        | 0.15                    | 0.228                | 0.64                |
| HER2                        | 0.08                    | 0.16                 | 0.03                |
| p53                         | 0.5                     | 0.268                | 0.455               |

and p53 expressions and BV response rate (respectively p=0.256, p=0.832, p=0.189, p=0.131) (Table 2).

Perineural invasion, leniovascular invasion and differentiation of the tumor specimens were compared with expression of VEGF, PTEN, HER2 and p53. Statistically significant difference was not found (Table 3).

Discussion

Biologic targeted therapies are so named because their activity is restricted to impeding one or several pathways within tumor cells. Decisions regarding treatment options were dependent on performance status, age, organ function and previous treatment decision in the past (Asghar et al., 2010). Nowadays Kras mutation in the EGFR pathway is predictive for Cetuximab therapy. KRAS mutation has changed the approach from universal chemotherapy to a more personalized. Multiple factors, including relatively low response rates and high costs for targeted agents, are driving the search to identify further biomarkers within the EGFR/Ras/Raf/Mek/Erk and PTEN/P13K/AKT signaling pathways. Bevacizumab (BV) targets the angiogenesis needed for tumor growth by inhibition of the vascular endothelium growth factor VEGF pathway (Cacheux et al., 2011). Any predictive biomarker has been identified.

We aimed to analyse some biomarkers that can predict BV response in this study (Asghar et al., 2010).

PTEN loss, VEGF, HER2 expressions are responsible for tumor angiogenesis, cell proliferation, apoptosis regulation by activation by different pathways (Asghar et al., 2010; Cacheux et al., 2011). The primary function of the p53 protein is as a tumour suppressor (Munro et al., 2005).

Numerous retrospective studies showed the prognostic value of VEGF expression in CRC. High VEGF expression in tumor tissue indicated a shorter relapse free survival and overall survival was reported by Des Guetz et al. (2006).

No conclusive evidence yet exists that VEGF is a predictive biomarker of efficacy for antiangiogenic therapy (Asghar et al., 2010). Pretreatment VEGF levels revealed no significant relationship between clinical response and time to progression (Longo et al., 2007). We didn’t find any correlation between VEGF expression and BV response but statistically significant difference was found OS between negative expression of VEGF in our study. Jalbä et al. (2011) showed VEGF-A expression as a poor prognostic marker for CRC in their study (Jalbä et al., 2011). In other study; there was found no correlation between treatment response and VEGF expression within the tumour tissue (Pohl et al., 2011).

In our study we found longer overall survival rates with negative VEGF expression but we didn’t find any correlation between BV treatment response and VEGF expression like other studies.

PTEN expression rate was found as 30-40% in sporadic breast, lung, and colorectal cancer (Hawkes et al., 2010). We found in the rate of 35% PTEN loss in m CRC. Colakoglu et al. (2008) have reported PTEN expression and its correlation with the prognostic factors in CRC. PTEN expression showed a negative correlation with young age, female sex, and left-sided (distal) tumors. On multivariate analysis, low PTEN expression (PTEN loss) was noted as an independent parameter for local recurrence (P=0.024) in their study (Colakoglu et al., 2008). We analysed PTEN as prognostic and predictive biomarker in m CRC. We didn’t find any correlation between PTEN expression and BV response and the other parameters (LVI, PNI, differentiation). OS difference was not found between PTEN, VEGF, HER2, p53 expression rates in our study.

Zhou et al. (2004) reported that inactivation of PTEN gene and over-expression of VEGF contribute to the neoangiavasulation and progression of gastric cancer. PTEN related angiogenesis might be attributed to its up-regulation of VEGF expression for their report. PTEN and VEGF could be used as the markers reflecting...
Oguz Kara et al
Asian Pacific Journal of Cancer Prevention, Vol 13, 2012

the biologic behaviors of tumor and viable targets in therapeutic approaches to inhibit angiogenesis of gastric cancers (Zhou et al., 2004). In our study we didn’t find any correlation between VEGF and PTEN expression.

Herreros-Villanueva et al. (2011) have demonstrated compelling evidence supporting HER2 gene amplification in colorectal carcinoma. These data appear to speculate that some patients who present HER2 gene amplification could respond to anti-HER2 therapies, such as Trastuzumab.

In our study 82.4% patients had negative HER2 expression. None of the patients had 3(+) strong expression. In the rate of 17.6% 1(+) and 2(+) HER2 expression were determined in our study. We analysed HER2 expression as prognostic and predictive factor in m CRC. We didn’t find any correlation between HER2 expression and BV response rate. There wasn’t statistically significant difference between OS and HER2 expression. Correlation was not found between VEGF expression and HER2 expression. VEGF is one of the most potent inducers of angiogenesis where as HER2/ neu has been implicated in the regulation of VEGF. HER2 overexpression is correlated with VEGF expression in breast cancer (Yen et al., 2000; 2002; Yang et al., 2002) but we didn’t find any correlation in this study.

HER2 expression led to translational up regulation of VEGF and increased angiogenesis through ERK, PI3K/Akt, mTOR and p70S6K (Yen et al., 2000).

Previous studies demonstrating that the expression of p53 in tumor tissues was associated with the reduced disease-free interval with anti-VEGF monoclonal antibody (Klos et al., 2006; Murad et al., 2007; Li et al., 2011).

The primary function of the p53 protein is as a tumour suppressor. It can induce temporary cell cycle arrest, permitting time for repair of any DNA damage; it can induce apoptosis; and it can impose a permanent block on any future attempts at cell division (Lohrum et al., 2001).

The results from the studies on patients treated with potentially curative surgery again suggest that abnormalities of p53 may have no significant impact upon the response of colorectal cancer to chemotherapy (Lohrum et al., 2001).

We didn’t find any correlation between p53 expression and BV response. Statistically significant difference was not found between difference expression rates of p53 and OS. P53 is not associated with poor prognosis in our study.

VEGF is a key player in tumor angiogenesis and the target for the monoclonal antibody (MoAb) bevacizumab, which is currently licensed for use in mCRC. Despite numerous studies, an equivalent predictive biomarker for bevacizumab has not been identified. Preclinical work indicates that inhibition of the insulin growth factor receptor (IGFR) pathway stops cellular transformation and tumor regression, thus identifying this pathway as a strong potential target for anticancer drug development and the identification of novel biomarkers. The molecules KRAS, BRAF, NRAS, PTEN, PI3K, VEGF, IGF-1R, and IGF binding protein 3 are discussed. Currently, KRAS is the only biomarker used in clinical practice for mCRC. Pending the results of ongoing and future studies, additional biomarkers will be tested, tailoring our approach to targeted therapy in mCRC (Asghar et al., 2010).

Targeted MoAbs to VEGFR and EGFR are well-established therapies for the treatment of colorectal cancer. The costs and toxicities associated with these novel treatments are not insignificant, and therefore molecular markers that predict treatment efficacy are needed to individualize the therapy administered to each patient (Chua et al., 2009).

We didn’t find any correlation between BV response and different biomarkers expression like the literature. VEGF and HER2 expressions rates were correlated each other for our study. VEGF negative expression is associated higher OS rate.

In conclusion, BV is important for treatment in m CRC. We aimed to analyse predictive biomarker for BV treatment. In our study we didn’t find any correlation between BV treatment and VEGF, PTEN, HER2 and p53 expression, we need prospective study.

References

Ahwon L, Woo CP, Hyeon WY, et al (2007). Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol, 37, 708-14.

Asghar U, Hawkes E, Cunningham D (2010). Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer, 9, 274-81.

Cacheux W, Le Tourneau C, Baranger B, Mignot L, Mariani P (2011). Targeted biotherapy in metastatic colorectal carcinoma: Current practice. J Visc Surg, 148, 12-8.

Christos NP, Christopher JL (2004). Bortezomib as a potential treatment for prostate cancer. Cancer Res, 64, 5036-43.

Chua W, Moore MM, Charles KA, Clarke SJ (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Curr Opin Mol Ther, 11, 611-22.

Colakoglu T, Yildirim S, Kayaselcuk F, et al (2008). Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Ann J Surg, 195, 719-25.

Des GG, Uzzan B, Nicolas P, et al (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer, 94, 1823-32.

Hawkes E, Cunningham D (2010). Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol, 28, 529-31.

Herreros-Villanueva M, Rodrigo M, Claver M, et al (2011). KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep, 38, 1315-20.

Jalbá CS, Jalbá BA, Nicula C, et al (2011). Clinical relevance of vascular endothelial growth factor-A in colorectal cancer. Mol Biol Rep, 38, 1315-20.

Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.

Klos KS, Wyszomierski SL, Sun M, et al (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/ p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res, 66, 2028-37.

Li Q, Wang D, Li J, Chen P (2011). Clinicopathologic and prognostic significance of HER-2/neu and VEGF expression
PTEN, VEGF, HER2 and P53 Status and Bevacizumab Response of Colorectal Cancer Patients

in colon carcinoma. BMC Cancer, 11, 277.

Lohrum MA, Woods DB, Ludwig RL, Bálint E, Vousden KH (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol, 21, 8521-32.

Longo R, Gasparini G (2007). Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol, 60, 151-70.

Munro AJ, Lain S, Lane DP (2005). p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer, 92, 434-44.

Murad JC, Ribeiro U Jr, Safatle-Ribero AV, et al (2007). Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma. Hepatogastroenterology, 54, 1029-33.

Perrone G, Santini D, Verzi A, et al (2006). COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol, 59, 492-6.

Pohl M, Werner N, Munding J, et al (2011). Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol, 49, 1398-406.

Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM (2009). Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol, 4, 41.

Yang W, Klos K, Yang Y, et al (2002). ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer, 94, 2855-61.

Van CE, Köhne CH, Láng I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 29, 2011-9.

Wei Q, Shui Y, Zheng S, et al (2011). EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep, 25, 3-11.

Wong R, Cunningham D (2008). Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol, 26, 5668-70.

Yen L, Benlimame N, Nie ZR, et al (2002). Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell, 13, 4029-44.

Yen L, You XL, Al Moustafa AE, et al (2000). Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 19, 3460-9.

Zhou YJ, Xiong YX, Wu XT, et al (2004). Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol, 10, 3225-9.